UPPSALA, Sweden, Jan 31, 2017 /PRNewswire/ -- The number of shares and votes in Orexo AB has changed as a result of the exercise of warrants in connection with the company's incentive programs.
Today, the last trading day of the month, there are in total 34,874,585 shares - whereof 34,539,585 are ordinary shares and 335,000 class C shares - and 34,573,085 votes in the company.
For further information, please contact:
Orexo AB (publ.)
Lena Wange, IR & Communications Manager
Tel: 018 780 88 00
Orexo is a specialty pharmaceutical company commercializing its proprietary product Zubsolv® for treatment of opioid dependence in the US. Zubsolv is an advanced formulation of buprenorphine and naloxone using Orexo's unique knowledge and expertise in sublingual drug delivery. R&D is focusing on reformulation of known substances to new improved products that meet great unmet medical needs by using its patented proprietary technologies. Orexo's share is listed on Nasdaq Stockholm Exchange Mid Cap (STO: ORX) and is available as ADRs on OTCQX (ORXOY) in the US. Orexo's global headquarters and R&D are based in Uppsala, Sweden.
The information was submitted for publication at 5:45pm CET, January 31, 2017
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/number-of-shares-and-votes-in-orexo-300399606.html